📊 APLMW Key Takeaways
Is Apollomics Inc. (APLMW) a Good Investment?
Apollomics Inc. presents an uninvestable opportunity due to complete absence of financial data, indicating either pre-revenue status or failure to file required SEC documents. Without any revenue, profitability metrics, balance sheet data, or cash flow information, fundamental analysis cannot be performed, and the company's viability cannot be assessed.
Apollomics' fundamentals are very weak: despite an $8.5 million revenue contribution in the first half of 2025 and a narrower net loss, the company remained loss-making and its balance sheet deteriorated sharply. By June 30, 2025, cash had fallen to about $2.1 million, current liabilities exceeded current assets, and total equity had turned negative, indicating severe financial stress and poor growth quality.
Why Buy Apollomics Inc. Stock? APLMW Key Strengths
- No strengths identified
- Net loss improved materially in H1 2025 versus H1 2024
- R&D expense declined significantly, reducing cash burn
- The company generated reported revenue in H1 2025 after having no revenue in prior comparable periods
APLMW Stock Risks: Apollomics Inc. Investment Risks
- No revenue reported - pre-revenue or non-operating status
- Complete absence of financial statements and balance sheet data
- No cash flow information available - unable to assess burn rate or runway
- Lack of insider activity and minimal SEC filing history suggests limited operational activity
- Impossible to evaluate financial health, liquidity, or solvency with available data
- Pharmaceutical sector requires significant R&D investment; unknown funding status poses existential risk
- Cash and cash equivalents dropped from about $9.8 million at December 31, 2024 to about $2.1 million at June 30, 2025
- Balance sheet weakened to negative equity and negative working capital by June 30, 2025
- Revenue quality appears weak because recent revenue was not supported by a durable, profitable operating model
Key Metrics to Watch
- Revenue recognition and operating metrics
- Cash position and burn rate
- Clinical trial progress and regulatory milestones
- cash runway and quarterly operating cash burn
- working capital and whether equity returns to positive territory
Apollomics Inc. (APLMW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
APLMW Profit Margin, ROE & Profitability Analysis
APLMW vs Healthcare Sector: How Apollomics Inc. Compares
How Apollomics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Apollomics Inc. Stock Overvalued? APLMW Valuation Analysis 2026
Based on fundamental analysis, Apollomics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Apollomics Inc. Balance Sheet: APLMW Debt, Cash & Liquidity
APLMW Revenue Growth, EPS Growth & YoY Performance
APLMW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Apollomics Inc. (CIK: 0001944885)
📋 Recent SEC Filings
❓ Frequently Asked Questions about APLMW
What is the AI rating for APLMW?
Apollomics Inc. (APLMW) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are APLMW's key strengths?
Claude: . ChatGPT: Net loss improved materially in H1 2025 versus H1 2024. R&D expense declined significantly, reducing cash burn.
What are the risks of investing in APLMW?
Claude: No revenue reported - pre-revenue or non-operating status. Complete absence of financial statements and balance sheet data. ChatGPT: Cash and cash equivalents dropped from about $9.8 million at December 31, 2024 to about $2.1 million at June 30, 2025. Balance sheet weakened to negative equity and negative working capital by June 30, 2025.
What is APLMW's revenue and growth?
Apollomics Inc. reported revenue of N/A.
Does APLMW pay dividends?
Apollomics Inc. does not currently pay dividends.
Where can I find APLMW SEC filings?
Official SEC filings for Apollomics Inc. (CIK: 0001944885) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is APLMW's EPS?
Apollomics Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is APLMW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Apollomics Inc. has a SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is APLMW stock overvalued or undervalued?
Valuation metrics for APLMW: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy APLMW stock in 2026?
Our dual AI analysis gives Apollomics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is APLMW's free cash flow?
Apollomics Inc.'s operating cash flow is N/A, with capital expenditures of N/A.
How does APLMW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).